ClearPoint Neuro Reports Third Quarter 2025 Results

Core Insights - ClearPoint Neuro, Inc. reported a quarterly revenue of $8.9 million, reflecting a 9% year-over-year increase compared to Q3 2024 [1] - The company narrowed its full-year revenue forecast for 2025 to a range between $36.0 million and $38.0 million [1] - ClearPoint Neuro continues to support over 60 active biopharma partners, with nine partner programs accepted for FDA expedited review [1] Financial Performance - Quarterly revenue reached $8.9 million, marking a 9% increase year-over-year [1] - Cash and cash equivalents totaled $38.2 million as of September 30, 2025 [1] Strategic Developments - The company completed the transition to its new Pre-clinical CRO Facility, ClearPoint Advanced Laboratories, which became operational in Q4 2025 [1] - ClearPoint Neuro announced the development of a prototype Robotic Neuro-Navigation System to enhance minimally invasive cranial surgical procedures [1] - The company received FDA 510(k) clearance for the ClearPoint PRISM Laser Therapy System, expanding its compatibility with 1.5T MRI guidance [1] Regulatory and Market Expansion - ClearPoint Neuro achieved several expanded regulatory approvals for product use in Canada, Hong Kong, and Taiwan, totaling 34 countries worldwide [1] - An agreement was signed for the acquisition of IRRAS Holdings, Inc., which will enhance the company's presence in the neurocritical care space [1] - Five new global customers were activated in the third quarter [1]